23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Study aims to fill research gap and empower people through access to information about their health
該研究旨在填補研究空白,並通過獲取有關其健康情況的信息使人們得以掌權。
SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic Insights into Colorectal Cancer in the Black Community Study is part of 23andMe's continued efforts to raise awareness about important health conditions that touch many individuals but disproportionately impact the Black community. Through this study, 23andMe and the Alliance aim to recruit individuals who have African ancestry or identify as Black, African American, or of African descent who have been diagnosed with colorectal cancer, which includes colon cancer and cancer of the rectum.
加利福尼亞州聖尼維爾,2024年6月4日(全球新聞通訊社)-23andMe控股有限公司(Nasdaq: ME)(23andMe)是一家領先的基因健康和生物製藥公司,並與結直腸癌聯盟(Alliance),這是最大的非營利性組織,致力於終結結直腸癌,在黑人/非裔美國人社區開展協作,以幫助推進結直腸癌的研究。這項研究正在招募18歲或以上、居住在美國並被診斷爲患有直腸癌的黑人和非裔美國人。研究是23andMe持續努力提高意識,了解很多人但對黑人社區產生不成比例影響的重要健康問題的一部分。通過該研究,23andMe和聯盟旨在招募具有非洲血統或認爲自己屬於黑人、非裔美國人或非洲血統的人群,這些人被診斷爲患有結直腸癌,包括結腸癌和直腸癌。
How colorectal cancer impacts the Black community
結直腸癌對黑人社區的影響
In the United States, Black and African Americans tend to experience earlier onset and worse disease outcomes for colorectal cancer. Colorectal cancer is the third most common cancer among men and women in the Black community. Black Americans have the second-highest incidence and mortality rates of colorectal cancer in the U.S. They are 15% more likely to develop colorectal cancer and 35% more likely to die from it than non-Hispanic white Americans. Rates of early onset colorectal cancer in the Black community are also increasing. "At the Alliance, we empower people to better navigate colorectal cancer outcomes in their lives and communities," said Angele Russell, Senior Director of Partnerships & Health Equity at the Colorectal Cancer Alliance. "This includes increasing awareness among young Black people who might not know their risk factors and providing resources aimed at early detection."
在美國,黑人和非裔美國人往往會經歷更早的結直腸癌發病年齡和更差的疾病結果。結直腸癌是黑人社區男性和女性中第三種最常見的癌症。黑人美國人在美國患結直腸癌的發病率和死亡率排名第二,他們患結直腸癌的幾率比非拉丁裔白人美國人高15%,死亡率比非拉丁裔白人美國人高35%。黑人社區早髮結直腸癌的發病率也在增加。「在聯盟中,我們賦予人們更好地引導他們的生活和社區中的結直腸癌結果的能力」,結腸癌聯盟的合作伙伴關係和健康公平的高級總監安傑爾·拉塞爾(Angele Russell)說。「這包括提高年輕黑人對他們可能不知道的風險因素的認識,並提供旨在早期檢測的資源。」在美國,黑人和非裔美國人往往會經歷更早的結直腸癌發病年齡和更差的疾病結果。在美國,黑人和非裔美國人往往會經歷更早的結直腸癌發病年齡和更差的疾病結果。結直腸癌是黑人社區男性和女性中第三種最常見的癌症。黑人美國人在美國患結直腸癌的發病率和死亡率排名第二,他們患結直腸癌的幾率比非拉丁裔白人美國人高15%,死亡率比非拉丁裔白人美國人高35%。黑人社區早髮結直腸癌的發病率也在增加。「在聯盟中,我們賦予人們更好地引導他們的生活和社區中的結直腸癌結果的能力」,結腸癌聯盟的合作伙伴關係和健康公平的高級總監安傑爾·拉塞爾(Angele Russell)說。「這包括提高年輕黑人對他們可能不知道的風險因素的認識,並提供旨在早期檢測的資源。」
Addressing the research gap
23andMe提供報告,其中包括基於統計模型(稱爲多基因分數(PRS))的報告。PRS報告是23andMe科學家和臨床專家使用公司的基因和自報告健康信息數據庫開發的,這些信息由同意參與研究的研究參與者貢獻。23andMe將結直腸癌作爲進一步研究的重點,因爲它是最常見的癌症之一,但具有有效的篩查和預防生活方式因素。但是,新的結直腸癌報告僅適用於歐洲和拉丁裔/西班牙裔血統的人群,因爲還沒有足夠的數據爲其他族裔提供結果-這是關於基因研究和多基因分數的歷史性問題。
23andMe offers reports, among which are those based on statistical models known as polygenic scores (PRS). The PRS reports are developed by 23andMe scientists and clinical experts using the company's database of genetic and self-reported health information contributed by consented research participants. 23andMe prioritized colorectal cancer for additional research as it is one of the most common cancers but has effective screening and preventive lifestyle factors. However, the new colorectal cancer report is only available for those of European and Latino/Hispanic descent, as there is not yet enough data to provide a result for those of other ethnicities–a historical issue with genetic research and polygenic scores at large.
「現在,黑人社區的結直腸癌研究存在空白,」23andMe負責多樣性計劃和研究倡導夥伴關係的首席程序經理Anjali Shastri博士說。「我們開展了這項研究以幫助填補空白。通過這項研究,我們希望改進多基因分數並加強我們對黑人和非裔美國人的認識,了解他們的基因如何影響患此疾病的機會。」
"Right now, there's a gap in research on colorectal cancer in the Black community," said Anjali Shastri, Ph.D., Principal Program Manager at 23andMe, Lead for diversity programs and advocacy partnerships for research. "We developed this study to help fill in the gap. Through this study, we hope to improve the polygenic score and our ability to inform Black and African Americans about how their genetics impact their chance of developing this condition."
結直腸癌聯盟的首席執行官Michael Sapienza說:「通過與23andMe的合作,我們希望教育黑人社區了解他們的家族歷史和風險因素的重要性,以幫助預防結直腸癌,或在最易治療的早期階段發現它。」
Michael Sapienza, Chief Executive Officer at the Colorectal Cancer Alliance said, "Through this collaboration with 23andMe, we want to educate the Black community about the importance of knowing their family history and risk factors to help prevent colorectal cancer or find it at early stage when it is most treatable."
23andMe提供報告,其中包括基於統計模型(稱爲多基因分數(PRS))的報告。PRS報告是23andMe科學家和臨床專家使用公司的基因和自報告健康信息數據庫開發的,這些信息由同意參與研究的研究參與者貢獻。23andMe將結直腸癌作爲進一步研究的重點,因爲它是最常見的癌症之一,但具有有效的篩查和預防生活方式因素。但是,新的結直腸癌報告僅適用於歐洲和拉丁裔/西班牙裔血統的人群,因爲還沒有足夠的數據爲其他族裔提供結果-這是關於基因研究和多基因分數的歷史性問題。
How this study can help further research
黑人社區結直腸癌的遺傳洞見
The Genetic Insights into Colorectal Cancer in the Black Community Study is recruiting Black and African American individuals who are 18 years or older, live in the United States, and have been diagnosed with colorectal cancer.
本基金尋求於東歐地區註冊的主要權益關聯發行人的長期升值投資。這項研究正在招募18歲或以上、居住在美國並被診斷爲患有直腸癌的黑人和非裔美國人。對於那些想獲取有關如何參與此研究的其他信息的人,可以在研究着陸頁上了解更多信息。參與這項研究的人將有機會通過23andMe + 高級會員資格免費訪問健康報告。
For those who would like additional information about how to participate in this research they can learn more on the study landing page. People who participate in this research study will have the option to access health reports through a 23andMe+ Premium membership at no cost.
對於那些想獲取有關如何參與此研究的其他信息的人,可以在研究着陸頁上了解更多信息。參與這項研究的人將有機會通過23andMe + 高級會員資格免費訪問健康報告。
Those who would like more information about this study can learn more here. Those interested in learning more about the signs and symptoms of colorectal cancer and how to get screened today can learn more here.
About 23andMe
關於23andMe
23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit www.23andMe.com.
23andMe是一家以基因爲導向的消費者醫療保健和生物製藥公司,爲創造更健康的未來而努力。欲了解更多信息,請訪問www.23andMe.com。23andMe是一家以基因爲導向的消費者醫療保健和生物製藥公司,爲創造更健康的未來而努力。欲了解更多信息,請訪問www.23andMe.com。.
About the Colorectal Cancer Alliance
關於結直腸癌聯盟
The Colorectal Cancer Alliance empowers a nation of passionate and determined allies to prevent, treat, and overcome colorectal cancer in their lives and communities. Founded in 1999 and headquartered in Washington, D.C., the Alliance advocates for prevention, magnifies support, and accelerates research. We are the largest national nonprofit dedicated to colorectal cancer, and we exist to end this disease in our lifetime. For more information, visit www.colorectalcancer.org.
結直腸癌聯盟賦予全國充滿激情和決心的盟友預防、治療和克服結直腸癌,並且支持腫瘤研究。我們成立於1999年,總部位於華盛頓特區,該聯盟倡導預防,放大支持,加速研究。我們是全美最大的致力於結直腸癌的非盈利組織,我們的存在旨在在我們的有生之年結束這種疾病。欲了解更多信息,請訪問www.colorectalcancer.org.
Forward-Looking Statements
前瞻性聲明
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
本新聞稿包含根據美國證券法第27A條及其修正案和第21E條及其修正案的前瞻性聲明,其中包括除歷史事實陳述外,本新聞稿包含或納入的所有陳述均爲前瞻性聲明。「相信」、「預計」、「估計」、「計劃」、「期望」、「意向」、「可能」、「能夠」、「應該」、「潛在」、「可能」、「項目」、「預測」、「持續」、「將」、「時間表」、「將會」或類似用語的否定形式或其他變體,旨在識別前瞻性聲明,雖然並非所有前瞻性聲明都包含這些識別單詞。這些前瞻性聲明是基於23andMe公司對未來事件和各種假設的當前期望和預測,23andMe無法保證實際達成其在前瞻性聲明中披露的計劃、意圖或預期,並且您不應對23andMe的前瞻性聲明過度依賴。這些前瞻性聲明涉及多種風險、不確定因素(其中許多超出23andMe的控制範圍)或其他假設,這些因素可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的結果或表現有所不同。此外,這些前瞻性聲明通常還普遍受到可能會在時間上發生變化的其他風險和不確定性的影響,如公司向證券交易委員會提交的其他文件中不時描述的那樣,在公司的最新年度報告(表格10-K)的第1A項「風險因素」下,提交給證券交易委員會,並由我們的一季度報告(表格10-Q)和目前的報告進行修訂和更新。本聲明的表述日期爲新聞發稿日,除法律要求外,23andMe不承擔更新這些表述的義務,無論有無新信息、進展或其他情況。
Contacts
聯繫方式
23andMe:
Media: press@23andMe.com
Investors: investors@23andMe.com
23andMe:
媒體:press@23andMe.com
投資者:investors@23andMe.com
Colorectal Cancer Alliance:
Media: eblasi@CCAlliance.org
結直腸癌聯盟:
媒體:eblasi@CCAlliance.org